Although the specificity of Raftlin as a biomarker for otosclerosis may be limited due to its elevation in various inflammatory and systemic diseases, recent studies have demonstrated its relevance in several otolaryngological and non-otolaryngological conditions. Here, RFTN1 is linked to otosclerosis.